Search Results
Another Win for Lymphoma Patients
The U.S. Food and Drug Administration’s latest approval of a blood cancer therapy is encouraging news for a group of lymphoma patients with a very rare subset of the disease called primary mediastinal large B-cell lymphoma (PMBCL). The approval is for patients who have relapsed after two or more prior lines of therapy or who did not respond to therapy at all.
Heart Disease in Lymphoma Survivors
Matthew Matasar is a hematology and oncology specialist at Memorial Sloan-Kettering Cancer Center in New York City. He has a Translational Research Program grant through The Leukemia & Lymphoma Society and is investigating which Hodgkin lymphoma survivors are at greater risk for developing heart disease after receiving radiation therapy to the chest and what diagnostic tests are best.
A Vaccine to Treat Mantle Cell Lymphoma?
Ronald Levy, professor of medicine and former chief of the Division of Oncology at Stanford University School of Medicine, helped develop and test the first US Food and Drug Administration (FDA)-approved monoclonal antibody against cancer for the treatment of B-cell lymphoma. Rituximab is now a standard of treatment alone and also in combination with chemotherapy regimens.
Significant Advance for Hodgkin Lymphoma Patients
The Food & Drug Administration’s accelerated approval of an immunotherapy for patients with Hodgkin lymphoma who have failed other treatments is a positive development for patients who face a very poor prognosis.
While Hodgkin lymphoma is now considered one of the most curable forms of cancer – with a more than 86 percent five-year-survival rate overall – those patients who relapse after treatment have a much reduced chance of survival.
A Hodgkin Lymphoma Survivor’s “New Normal”
My life with cancer began five days before my wedding when I was 25 years old. On August 2, 2004, I was at a family birthday party when I felt a lump protruding out of my neck. After the party, I rushed over to see my stepdad who is a doctor.
Although he knew that the position of the lump at my age was not a good sign, he calmed me down and gave me antibiotics. After months of planning for the wedding, he knew how important it was for me to walk down the aisle.
Lymphoma diagnosis, survival rate by age, prognosis, and treatment
Table of contents:
Leukemia vs. lymphoma: What you need to know
Table of contents
Ask the Doctor Part 2: Five Questions about Lymphoma
Lymphoma survivor, Jessica Melore talks to Dr. Nichols about the Latest in Lymphoma Research and Treatment
Lymphoma
Lymphoma is the name for a group of blood cancers that develop in the lymphatic system. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL).
FDA Approves Important New Treatment for Hodgkin lymphoma
The U.S. Food & Drug Administration today announced the first change in 40 years in the standard way that patients newly diagnosed with advanced Hodgkin lymphoma (HL) should be treated.
Today’s FDA approval of brentuximab vedotin (Adcetris®) in combination with chemotherapy to treat Stage 3 and Stage 4 HL patients who are newly diagnosed and have received no prior treatment, is significant for a patient population that has seen no change in the standard of care in more than four decades.
Looking Back at Lymphoma (23 Years Later!)
Life is a journey and I can personally attest to the many obstacles, emotions, milestones and lessons learned that come with it.
A New CAR-T Approval Brings Hope for Mantle Cell Lymphoma Patients
The U.S. Food and Drug Administration (FDA) today announced its approval for a breakthrough treatment that will bring the promise of immunotherapy and new hope to thousands of patients diagnosed with mantle cell lymphoma (MCL) whose previous treatments fail to bring them lasting remissions.
Every Year Counts: Celebrating My Healing from Hodgkin Lymphoma
Many blood cancer survivors remember the day they were diagnosed, and they never forget it. For Racheli Alkobey Peltier—Director of Diversity, Equity, and Inclusion at The Leukemia & Lymphoma Society (LLS)— when that date comes around, it’s a chance to mark her progress.
Each year, Racheli marks important milestones in her experience with blood cancer—taking time to reflect, feel gratitude, and look ahead. These dates are her “cancerversaries.”
Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common.
Lymphoma
Please note that these resources are regularly reviewed to ensure that links still work correctly and that the resources listed continue to be helpful to our visitors. If you find that a link isn't working or information is incorrect, please email infocenter@lls.org. If you would like for us to consider adding your organization to this resource, please complete and submit this form.
My Journey Through Stage IV Non-Hodgkin Lymphoma
Brittany Daniel is an actress best known for her role in the television series “Sweet Valley High” and the film, “Joe Dirt,” and a lifestyle blogger at The Sweet Life By Brittany + Cynthia Daniel. She and her husband, Adam, will participate in The Leukemia Cup Regatta in San Francisco (www.sflcr.org) on October 22.
#ASCO20: Cancer in the Time of COVID-19, and Progress in Myeloma and Lymphoma
As National Cancer Research Month (May) winds down, it seems timely to reflect on progress in cancer treatments. And that is precisely what we will do this weekend.
Hodgkin Lymphoma
Hodgkin Lymphoma (HL)- Is a cancer that affects the lymphatic system, which is part of the body's immune system
- Is one of the most curable forms of cancer
- Is named for Dr. Thomas Hodgkin who, in 1832, described several cases of people with symptoms of a cancer involving the lymph nodes. The disease was called "Hodgkin's disease" until it was officially renamed "Hodgkin lymphoma" in the late 20th century.
Click here to access Hodgkin lymphoma statistics.
Walgreens, The Leukemia & Lymphoma Society and Susan G. Komen Collaborating to Support Research in Tough-to-Treat Cancers and Increase Access to Care
In February, Walgreens launched their annual spring fundraiser for The Leukemia & Lymphoma Society and Susan G. Komen to enable research in tough-to-treat cancers and increase access to care with a pledge to contribute more than $25 million to the organizations, collectively, through 2024. Through a combination of online and in-store donations, the commitment enables research in metastatic breast and pediatric blood cancers, as well as increases access, treatment and support services for those living with these diseases.